Amyloid PET normalizes faster than CSF p-tau217 due to differential compartment kinetics (vascular vs. neuronal). Using amyloid PET alone for stopping may prematurely halt treatment before downstream tau pathology resolution. This hypothesis remains biologically plausible but lacks outcome validation—the clinical inference (dual threshold required) is not yet supported by data showing harm from amyloid-PET-only stopping.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["APP Full Length Membrane Protein"]
B["BACE1 Beta-Secretase Cleavage at beta-site"]
C["sAPPbeta + CTFbeta C-terminal Fragment"]
D["Gamma-Secretase Complex PSEN1/PSEN2"]
E["Abeta42 Peptide Amyloidogenic Fragment"]
F["Abeta Oligomers Toxic Aggregates"]
G["Amyloid Plaques Extracellular Deposits"]
H["ADAM10 Alpha-Secretase Non-amyloidogenic Path"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
A --> H
H -.->|"competes with BACE1"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#81c784,color:#81c784
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
9 citations9 with PMID5 mediumValidation: 0%7 supporting / 2 opposing
✓For(7)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
1
7
1
MECH 1CLIN 7GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
The sleep-wake cycle regulates brain interstitial …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF patients with early Alzheimer's disease receive anti-amyloid monoclonal antibody therapy and achieve amyloid PET negativity, THEN CSF p-tau217 will remain above the diagnostic threshold in at least 60% of participants at 12 months post-negativity, demonstrating temporal decoupling.
pendingconf: 0.45
Expected outcome: CSF p-tau217 remains elevated (above 23 pg/mL baseline-adjusted threshold) in ≥60% of amyloid PET-negative participants at month 12
Falsified by: CSF p-tau217 normalizes to baseline or below in >80% of participants within 6 months of achieving amyloid PET negativity, disproving the temporal decoupling mechanism
Method: Longitudinal cohort study (n=200) of amyloid-positive early AD participants receiving anti-amyloid therapy (lecanemab or donanemab), with amyloid PET and CSF p-tau217 measurements at months 0, 6, 12, 18, and 24
IF patients discontinue anti-amyloid therapy based solely on amyloid PET negativity while CSF p-tau217 remains ≥1.5x baseline, THEN they will demonstrate significantly greater cognitive decline (≥1.5 points/year on CDR-SB) compared to patients who continue therapy until both biomarkers normalize.
pendingconf: 0.35
Expected outcome: Mean annual CDR-SB decline of ≥1.5 points in the amyloid-PET-only stop group versus ≤0.8 points in the dual-threshold stop group over 24 months
Falsified by: No significant difference in CDR-SB decline between stopping rules (difference <0.5 points/year), indicating amyloid PET-only stopping does not produce worse outcomes and the dual threshold is unnecessary
Method: Preregistered RCT or propensity-matched cohort study comparing stopping strategies (amyloid PET-only vs. amyloid PET + CSF p-tau217 dual threshold) in 400 participants receiving anti-amyloid therapy, with cognitive assessments every 6 months for 24 months post-discontinuation
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
NA — Search for structure
Click to search RCSB PDB